Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 6/2012

01-06-2012 | Original Article

Prognostic Significance of High Phosphatase of Regenerating Liver-3 Expression in Patients with Gastric Cancer Who Underwent Curative Gastrectomy

Authors: Ahmet Bilici, Bala Basak Oven Ustaalioglu, Dilek Yavuzer, Mesut Seker, Alpaslan Mayadagli, Mahmut Gumus

Published in: Digestive Diseases and Sciences | Issue 6/2012

Login to get access

Abstract

Background

Although a close correlation between PRL-3 overexpression and lymph node metastasis has been reported in gastric cancer, its clinical utility as a useful prognostic molecular marker remains unclear.

Methods

Prognostic significance of PRL-3 expression was analyzed immunohistochemically in 110 patients with gastric cancer who had undergone curative gastrectomy.

Results

There was a significant correlation between gender, histology, lymph node metastasis, the presence of recurrence, and the level of PRL-3 expression. Recurrence in patients with high PRL-3 expression was significantly higher than that for patients with low PRL-3 expression (p < 0.001). The median overall survival (OS) time and 2-year OS rate for patients with high or moderate PRL-3 expressed tumors were worse than those of patients with low PRL-3 expressed tumor (p = 0.001). In addition, patients with low PRL-3 expression had a higher DFS rate and the median DFS interval than those of moderate or high PRL-3 expressed patients (p < 0.001). Multivariate analysis indicated that the rate of PRL-3 expression was an independent prognostic factor, in addition to the already-known important clinicopathological prognostic indicator for both DFS and OS.

Conclusions

The potential value of PRL-3 expression as a useful molecular marker in gastric cancer progression should be evaluated comprehensively; it may predict recurrence and poor prognosis in patients with gastric cancer after curative resection.
Literature
1.
2.
Desai AM, Pareek M, Nightingale PG, Fielding JW. Improving outcomes in gastric cancer over 20 years. Gastric Cancer. 2004;7:196–201.PubMedCrossRef
3.
4.
Galizia G, Lieto E, Orditura M, et al. Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery. World J Surg. 2007;31:1458–1468.PubMedCrossRef
5.
Kim JG, Sohn SK, Chae YS, Cho YY, et al. Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with gastric cancer. Ann Oncol. 2007;18:1030–1036.PubMedCrossRef
6.
Lyon MA, Ducruet AP, Wipf P, Lazo JS. Dual-specificity phosphatases as targets for antineoplastic agents. Nat Rev Drug Discov. 2002;1:961–976.PubMedCrossRef
7.
Cates CA, Michael RL, Stayrook KR, et al. Prenylation of oncogenic human PTP(CAAX) protein tyrosine phosphatases. Cancer Lett. 1996;110:49–55.PubMedCrossRef
8.
Zeng Q, Hong W, Tan YH. Mouse PRL-2 and PRL-3, two potentially prenylated protein tyrosine phosphatases homologous to PRL-1. Biochem Biophys Res Commun. 1998;244:421–427.PubMedCrossRef
9.
10.
Saha S, Bardelli A, Buckhaults P, et al. A phosphatase associated with metastasis of colorectal cancer. Science. 2001;294:1343–1346.PubMedCrossRef
11.
Bardelli A, Saha S, Sager JA, et al. PRL-3 expression in metastatic cancers. Clin Cancer Res. 2003;9:5607–5615.PubMed
12.
Peng L, Ning J, Meng L, Shou C. The association of the expression level of protein tyrosine phosphatase PRL-3 protein with liver metastasis and prognosis of patients with colorectal cancer. J Cancer Res Clin Oncol. 2004;130:521–526.PubMedCrossRef
13.
Kato H, Semba S, Miskad UA, et al. High expression of PRL-3 promotes cancer cell motility and liver metastasis in human colorectal cancer: a predictive molecular marker of metachronous liver and lung metastases. Clin Cancer Res. 2004;10:7318–7328.PubMedCrossRef
14.
Radke I, Götte M, Kersting C, et al. Expression and prognostic impact of the protein tyrosine phosphatases PRL-1, PRL-2, and PRL-3 in breast cancer. Br J Cancer. 2006;95:347–354.PubMedCrossRef
15.
Wang L, Peng L, Dong B, et al. Overexpression of phosphatase of regenerating liver-3 in breast cancer: association with a poor clinical outcome. Ann Oncol. 2006;17:1517–1522.PubMedCrossRef
16.
Ren T, Jiang B, Xing X, et al. Prognostic significance of phosphatase of regenerating liver-3 expression in ovarian cancer. Pathol Oncol Res. 2009;15:555–560.PubMedCrossRef
17.
Molleví DG, Aytes A, Padullés L, et al. PRL-3 is essentially overexpressed in primary colorectal tumours and associates with tumour aggressiveness. Br J Cancer. 2008;99:1718–1725.PubMedCrossRef
18.
Al-Aidaroos AQ, Zeng Q. PRL-3 phosphatase and cancer metastasis. J Cell Biochem. 2010;111:1087–1098.PubMedCrossRef
19.
Miskad UA, Semba S, Kato H, Yokozaki H. Expression of PRL-3 phosphatase in human gastric carcinomas: close correlation with invasion and metastasis. Pathobiology. 2004;71:176–184.PubMedCrossRef
20.
Miskad UA, Semba S, Kato H, et al. High PRL-3 expression in human gastric cancer is a marker of metastasis and grades of malignancies: an in situ hybridization study. Virchows Arch. 2007;450:303–310.PubMedCrossRef
21.
Li ZR, Wang Z, Zhu BH, et al. Association of tyrosine PRL-3 phosphatase protein expression with peritoneal metastasis of gastric carcinoma and prognosis. Surg Today. 2007;37:646–651.PubMedCrossRef
22.
Wang Z, He YL, Cai SR, et al. Expression and prognostic impact of PRL-3 in lymph node metastasis of gastric cancer: its molecular mechanism was investigated using artificial microRNA interference. Int J Cancer. 2008;123:1439–1447.PubMedCrossRef
23.
Edge SB, Byrd DR, Compton CC, et al., eds. AJCC (American Joint Committee on Cancer) Cancer Staging Manual. 7th ed. New York: Springer; 2010:117.
24.
Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma—2nd English edition. Gastric Cancer. 1998;1:10–24.PubMedCrossRef
25.
Zhang ZY, Zhou B, Xie L. Modulation of protein kinase signaling by protein phosphatases and inhibitors. Pharmacol Ther. 2002;93:307–317.PubMedCrossRef
26.
Stephens B, Han H, Hostetter G, et al. Small interfering RNA-mediated knockdown of PRL phosphatases results in altered Akt phosphorylation and reduced clonogenicity of pancreatic cancer cells. Mol Cancer Ther. 2008;7:202–210.PubMedCrossRef
27.
Guzińska-Ustymowicz K, Pryczynicz A. PRL-3, an emerging marker of carcinogenesis, is strongly associated with poor prognosis. Anticancer Agents Med Chem. 2011;11:99–108.PubMed
28.
Dai N, Lu AP, Shou CC, Li JY. Expression of phosphatase regenerating liver 3 is an independent prognostic indicator for gastric cancer. World J Gastroenterol. 2009;15:1499–1505.PubMedCrossRef
29.
Ooki A, Yamashita K, Kikuchi S, et al. Phosphatase of regenerating liver-3 as a prognostic biomarker in histologically node-negative gastric cancer. Oncol Rep. 2009;21:1467–1475.PubMed
30.
Wang Z, Cai SR, He YL, et al. High expression of PRL-3 can promote growth of gastric cancer and exhibits a poor prognostic impact on patients. Ann Surg Oncol. 2009;16:208–219.PubMedCrossRef
31.
Bessette DC, Qiu D, Pallen CJ. PRL PTPs: mediators and markers of cancer progression. Cancer Metastasis Rev. 2008;27:231–252.PubMedCrossRef
32.
Fiordalisi JJ, Keller PJ, Cox AD. PRL tyrosine phosphatases regulate rho family GTPases to promote invasion and motility. Cancer Res. 2006;66:3153–3161.PubMedCrossRef
33.
Liang F, Liang J, Wang WQ, et al. PRL3 promotes cell invasion and proliferation by down-regulation of Csk leading to Src activation. J Biol Chem. 2007;282:5413–5419.PubMedCrossRef
34.
Wang H, Quah SY, Dong JM, et al. PRL-3 down-regulates PTEN expression and signals through PI3K to promote epithelial-mesenchymal transition. Cancer Res. 2007;67:2922–2926.PubMedCrossRef
35.
Basak S, Jacobs SB, Krieg AJ, et al. The metastasis-associated gene Prl-3 is a p53 target involved in cell-cycle regulation. Mol Cell. 2008;30:303–304.PubMedCrossRef
36.
Polato F, Codegoni A, Fruscio R, et al. PRL-3 phosphatase is implicated in ovarian cancer growth. Clin Cancer Res. 2005;11:6835–6839.PubMedCrossRef
37.
Ooki A, Yamashita K, Kikuchi S, et al. Therapeutic potential of PRL-3 targeting and clinical significance of PRL-3 genomic amplification in gastric cancer. BMC Cancer. 2011;11:122.PubMedCrossRef
Metadata
Title
Prognostic Significance of High Phosphatase of Regenerating Liver-3 Expression in Patients with Gastric Cancer Who Underwent Curative Gastrectomy
Authors
Ahmet Bilici
Bala Basak Oven Ustaalioglu
Dilek Yavuzer
Mesut Seker
Alpaslan Mayadagli
Mahmut Gumus
Publication date
01-06-2012
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 6/2012
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-012-2076-9

Other articles of this Issue 6/2012

Digestive Diseases and Sciences 6/2012 Go to the issue

Original Article

A Comparative Evaluation of Early Stent Occlusion Among Biliary Conventional Versus Wing Stents

Correspondence

Discussion on the Esophageal Manometric Characteristics of Idiopathic and Reflux-associated Esophageal Spasm

Stanford Multidisciplinary Seminars

Abdominal Mass, Anemia, Diabetes Mellitus, and Necrolytic Migratory Erythema

Original Article

Comprehensive Self-Management Reduces the Negative Impact of Irritable Bowel Syndrome Symptoms on Sexual Functioning

Original Article

Corticosteroid Plus Pentoxifylline Is Not Better than Corticosteroid Alone for Improving Survival in Severe Alcoholic Hepatitis (COPE Trial)

Case Report

Azathioprine Induced Liver Injury: A Case Report
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits